Inhibition of Angiogenesis and HCT-116 Xenograft Tumor Growth in Mice by Kallistatin

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Aug 31

PMID 17729417

Citations 14

Authors

Yong Diao

Jian Ma

Wei-Dong Xiao

Jia Luo

Xin-Yan Li

Kin-Wah Chu

Peter W C Fung

Nagy Habib

Farzin Farzaneh

Rui-An Xu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the inhibitory effect of kallistatin (KAL) on angiogenesis and HCT-116 xenograft tumor growth.

Methods: Heterotopic tumors were induced by subcutaneous injection of 2 multiply 10(6) HCT-11 cells in mice. Seven days later, 2 multiply 10(11) rAAV-GFP or rAAV-KAL was injected intratumorally (n = 5 for each group). The mice were sacrificed at d 28, by which time the tumors in the rAAV-GFP group had grown to beyond 5% of the total body weight. Tumor growth was measured by calipers in two dimensions. Tumor angiogenesis was determined with tumor microvessel density (MVD) by immunohistology. Tumor cell proliferation was assessed by Ki-67 staining.

Results: Intratumor injection of rAAV-KAL inhibited tumor growth in the treatment group by 78% (171 +/- 52 mm(3)) at d 21 after virus infection compared to the control group (776 +/- 241 mm(3)). Microvessel density was significantly inhibited in tumor tissues treated with rAAV-KAL. rAAV-KAL also decreased the proportion of proliferating cells (Ki-67 positive cells) in tumors compared with the control group.

Conclusion: rAAV-mediated expression of KAL inhibits the growth of colon cancer by reducing angiogenesis and proliferation of tumor cells, and may provide a promising anti-angiogenesis-based approach to the treatment of metastatic colorectal cancer.

Citing Articles

The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature.

Giannas E, Kontovounisios C J Clin Med. 2023; 12(22).

PMID: 38002785 PMC: 10671867. DOI: 10.3390/jcm12227173.

Diabetes-induced upregulation of kallistatin levels exacerbates diabetic nephropathy via RAS activation.

Yang Y, He X, Cheng R, Chen Q, Shan C, Chen L FASEB J. 2020; 34(6):8428-8441.

PMID: 32352602 PMC: 7302980. DOI: 10.1096/fj.201903149R.

Cell surface expression of nucleolin mediates the antiangiogenic and antitumor activities of kallistatin.

Huang X, Wang X, Xie X, Zhang G, Lv F, Weng W Oncotarget. 2018; 9(2):2220-2235.

PMID: 29416766 PMC: 5788634. DOI: 10.18632/oncotarget.23346.

Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion.

Ma C, Luo C, Yin H, Zhang Y, Xiong W, Zhang T Gastric Cancer. 2017; 21(4):617-631.

PMID: 29243194 DOI: 10.1007/s10120-017-0787-5.

Kallistatin exerts anti-lymphangiogenic effects by inhibiting lymphatic endothelial cell proliferation, migration and tube formation.

Ma C, Yin H, Zhong J, Zhang Y, Luo C, Che D Int J Oncol. 2017; 50(6):2000-2010.

PMID: 28440474 PMC: 5435323. DOI: 10.3892/ijo.2017.3972.

References

Jain R, Duda D, Clark J, Loeffler J . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006; 3(1):24-40. DOI: 10.1038/ncponc0403. View

Xu R, Sun X, Tse L, Li H, Chan P, Xu S . Long-term expression of angiostatin suppresses metastatic liver cancer in mice. Hepatology. 2003; 37(6):1451-60. DOI: 10.1053/jhep.2003.50244. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U . Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 1999; 18(22):6240-8. PMC: 1171687. DOI: 10.1093/emboj/18.22.6240. View

Shi J, Zheng D, Liu Y, Sham M, Tam P, Farzaneh F . Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res. 2005; 65(5):1687-92. DOI: 10.1158/0008-5472.CAN-04-2749. View

Li C, Bowles D, Van Dyke T, Samulski R . Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005; 12(12):913-25. PMC: 1361306. DOI: 10.1038/sj.cgt.7700876. View

Diao Y, Xu R, Wang G, Zhao X . Adeno-associated virus mediated expression of human erythropoietin in vitro. Acta Pharmacol Sin. 2002; 23(1):55-8. View

Kisker O, Becker C, Prox D, Fannon M, Damato R, Flynn E . Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001; 61(20):7669-74. View

Gallagher J . Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest. 2001; 108(3):357-61. PMC: 209370. DOI: 10.1172/JCI13713. View

10.

Xu R, Janson C, Mastakov M, Lawlor P, Young D, Mouravlev A . Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 2001; 8(17):1323-32. DOI: 10.1038/sj.gt.3301529. View

11.

Bergers G, Benjamin L . Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3(6):401-10. DOI: 10.1038/nrc1093. View

12.

Miao R, Agata J, Chao L, Chao J . Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002; 100(9):3245-52. DOI: 10.1182/blood-2002-01-0185. View

13.

Kerbel R, Folkman J . Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2(10):727-39. DOI: 10.1038/nrc905. View

14.

Sun X, Krissansen G, Fung P, Xu S, Shi J, Man K . Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer. 2004; 113(4):670-7. DOI: 10.1002/ijc.20624. View

15.

Folkman J, Kalluri R . Cancer without disease. Nature. 2004; 427(6977):787. DOI: 10.1038/427787a. View

16.

Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View